Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK COVID-19 Infection Survey

Objectives: To assess the effectiveness of COVID-19 vaccination in preventing SARS-CoV-2 infection in the community. Design: Prospective cohort study. Setting: The UK population-representative longitudinal COVID-19 Infection Survey. Participants: 373,402 participants aged [≥]16 years contributing 1,610,562 RT-PCR results from nose and throat swabs between 1 December 2020 and 3 April 2021. Main outcome measures: New RT-PCR-positive episodes for SARS-CoV-2 overall, by self-reported symptoms, by cycle threshold (Ct) value (<30 versus [≥]30), and by gene positivity (compatible with the B.1.1.7 variant versus not). Results: Odds of new SARS-CoV-2 infection were reduced 65% (95% CI 60 to 70%; P<0.001) in those [≥]21 days since first vaccination with no second dose versus unvaccinated individuals without evidence of prior infection (RT-PCR or antibody). In those vaccinated, the largest reduction in odds was seen post second dose (70%, 95% CI 62 to 77%; P<0.001).There was no evidence that these benefits varied between Oxford-AstraZeneca and Pfizer-BioNTech vaccines (P>0.9).There was no evidence of a difference in odds of new SARS-CoV-2 infection for individuals having received two vaccine doses and with evidence of prior infection but not vaccinated (P=0.89). Vaccination had a greater impact on reducing SARS-CoV-2 infections with evidence of high viral shedding Ct<30 (88% reduction after two doses; 95% CI 80 to 93%; P<0.001) and with self-reported symptoms (90% reduction after two doses; 95% CI 82 to 94%; P<0.001); effects were similar for different gene positivity patterns. Conclusion: Vaccination with a single dose of Oxford-AstraZeneca or Pfizer-BioNTech vaccines, or two doses of Pfizer-BioNTech, significantly reduced new SARS-CoV-2 infections in this large community surveillance study. Greater reductions in symptomatic infections and/or infections with a higher viral burden are reflected in reduced rates of hospitalisations/deaths, but highlight the potential for limited ongoing transmission from asymptomatic infections in vaccinated individuals. Registration: The study is registered with the ISRCTN Registry, ISRCTN21086382.

[1]  Scott L. Bain,et al.  COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study , 2021, The Lancet.

[2]  Andrew L. Phillips,et al.  Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[3]  D. Bonsall,et al.  Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial , 2021, The Lancet.

[4]  A. Copas,et al.  Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study) , 2021, medRxiv.

[5]  D. Smith,et al.  Phylogenetic Analyses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.1.7 Lineage Suggest a Single Origin Followed by Multiple Exportation Events Versus Convergent Evolution , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  L. Rénia,et al.  Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study , 2021, The Lancet Microbe.

[7]  K. Mølbak,et al.  Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study , 2021, The Lancet.

[8]  N. G. Davies,et al.  Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.

[9]  G. Rodger,et al.  An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status , 2021, medRxiv.

[10]  William T. Harvey,et al.  Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.

[11]  C. M. Saad-Roy,et al.  Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes , 2021, Science.

[12]  Carl A. B. Pearson,et al.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.

[13]  N. Andrews,et al.  Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England , 2021, medRxiv.

[14]  M. Hernán,et al.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[15]  J. Farrar,et al.  Increased infections, but not viral burden, with a new SARS-CoV-2 variant , 2021 .

[16]  A. Chaillon,et al.  Phylogenetic analyses of SARS-CoV-2 B.1.1.7 lineage suggest a single origin followed by multiple exportation events versus convergent evolution , 2021, bioRxiv.

[17]  T. House,et al.  Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey , 2020, The Lancet Public Health.

[18]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[19]  C. Steves,et al.  Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults , 2020, The Lancet Healthy Longevity.

[20]  G. Rodger,et al.  Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison , 2020, The Lancet Infectious Diseases.

[21]  A. Charlett,et al.  Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[22]  J. Klausner,et al.  Self-Collected Oral Fluid and Nasal Swabs Demonstrate Comparable Sensitivity to Clinician Collected Nasopharyngeal Swabs for Covid-19 Detection , 2020, medRxiv.

[23]  Medicines And Healthcare Products Regulatory Agency , 2020, Definitions.

[24]  James E. Helmreich.  Regression Modeling Strategies with Applications to Linear Models, Logistic and Ordinal Regression and Survival Analysis (2nd Edition) , 2016 .

[25]  Communities.  English Indices of Deprivation 2010 , 2015 .

[26]  F. Schifano,et al.  Drug-related deaths in the UK: Annual Report 2011 [January-December 2010] : Drug-related deaths reported by Coroners in England, Wales, Northern Ireland, Guernsey, Jersey and the Isle of Man; Police forces in Scotland; & the Northern Ireland Statistics and Research Agency , 2012 .

[27]  A. Hall.  The United Kingdom Joint Committee on Vaccination and Immunisation. , 2010, Vaccine.

[28]  L. Toledo-Pereyra.  Trust , 2006, Mediation Behaviour.

[29]  Esteban Walker,et al.  Regression Modeling Strategies , 2003, Technometrics.

[30]  R. Brazier,et al.  Scottish Government , 1998, A Diverse Assembly.

[31]  V. Saliba,et al.  Public Health in England. , 1988, Public health.

[32]  A. Charlett,et al.  An observational study of SARS-CoV-2 infectivity by viral load and 1 demographic factors and the utility lateral flow devices to prevent 2 transmission 3 4 , 2021 .

[33]  Ping Li,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .

[34]  Marie ParkerJenkins,et al.  The Cabinet Office , 2002 .